Myeloma | Tumor

FDA Approves Pepaxto Combination for Relapsed/Refractory Multiple Myeloma

February 27th 2021, 12:30am

Article

The agency granted accelerated approval to Pepaxto in combination with dexamethasone in adult patients with relapsed or refractory multiple myeloma, who received at least four prior lines of therapy.

Novel CAR-T Cell Therapy Produces Sustainable Response in Patients with Relapsed Multiple Myeloma

February 26th 2021, 2:00pm

Article

Results from the phase 2 KarMMa trial showed that 73% of patients had a response to the CAR-T cell therapy, including 33% who experienced a complete response or better.

7 Recent Cancer Drug Approvals Patients May Have Missed

January 18th 2021, 7:00pm

Article

The Food and Drug Administration has had a busy winter so far, approving several new agents to treat a variety of cancers. Here are seven recent approvals that patients with cancer may have missed.

Triple Therapy with Darzalex Improves Pain, Quality of Life in Newly Diagnosed Multiple Myeloma Ineligible for Stem Cell Transplantation

January 14th 2021, 8:00pm

Article

Quality of life improved in patients treated with Darzalex, Revlimid and dexamethasone compared with Revlimid and dexamethasone, and were present regardless of age, functional status and the depth of their treatment response.

Novel Drug with Dexamethasone Safe in Heavily Pretreated Multiple Myeloma

January 13th 2021, 10:00pm

Article

Melflufen with dexamethasone was an effective treatment option for patients with relapsed or refractory multiple myeloma previously treated with a specific chemotherapy drug and/or an anti-CD38 monoclonal antibody.

A Granddaughter's Questions About Cancer

January 7th 2021, 5:00pm

Article

A caregiver discusses with her granddaughter the cancer diagnosis and treatment of a loved one.

FDA Lifts Hold on Trial Assessing CAR T-Cell Product for Relapsed or Refractory Multiple Myeloma

December 30th 2020, 7:00pm

Article

The Food and Drug Administration lifted a clinical hold on the MELANI-01 trial, evaluating UCARTCS1A, a CAR T-cell product in patients with relapsed or refractory multiple myeloma.

Clinical Trials on Smoldering Myeloma May Open Doors to More Precision Medicine

December 29th 2020, 10:00pm

Article

In an interview with CURE®, Dr. Irene M. Ghobrial discussed smoldering myeloma, a precursor condition that may progress to multiple myeloma, how to proceed if diagnosed with the condition and the available opportunities to participate in clinical trials to learn more.

The Top 10 'CURE Talks Cancer' Podcasts of 2020

December 27th 2020, 3:00pm

Article

Here are the top 10 episodes of the “CURE Talks Cancer” podcast from 2020.

Triple Therapy with Xpovio, Velcade and Dexamethasone Improved Progression-Free Survival in Multiple Myeloma

December 21st 2020, 4:00pm

Article

This treatment strategy contributed to a median progression-free survival of 13.93 months compared with 9.46 months in those treated with Velcade and dexamethasone.